Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.